Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

Researchers use highly accurate biomarker to measure aging in HIV infected patients

Researchers use highly accurate biomarker to measure aging in HIV infected patients

Thanks to combination antiretroviral therapies, many people with HIV can expect to live decades after being infected. Yet doctors have observed these patients often show signs of premature aging. [More]
Developing countries face health financing crisis due to low domestic investment, stagnating international aid

Developing countries face health financing crisis due to low domestic investment, stagnating international aid

Two major studies published in The Lancet reveal the health financing crisis facing developing countries as a result of low domestic investment and stagnating international aid, which could leave millions of people without access to even the most basic health services. [More]
Researchers develop novel method to store microfluidic devices for CD4 T cell testing

Researchers develop novel method to store microfluidic devices for CD4 T cell testing

Providing vital health care services to people in developing countries without reliable electricity, refrigeration and state-of-the-art medical equipment poses a number of challenges. Inspired by pregnancy tests, researchers from Florida Atlantic University, Stanford University, and Baskent University in Turkey, have developed a novel method to store microfluidic devices for CD4 T cell testing in extreme weather conditions for up to six months without refrigeration. [More]
Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Two separate studies presented today at The International Liver Congress 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with HIV and Hepatitis C virus (HCV). [More]
NHS England to provide crucial funding for Janssen's HIV treatment, REZOLSTA

NHS England to provide crucial funding for Janssen's HIV treatment, REZOLSTA

Janssen-Cilag Ltd today announced that NHS England will provide crucial funding for its once-daily, fixed-dose combination of darunavir and the pharmacoenhancer, cobicistat, called REZOLSTA. [More]
Study suggests strong treatment programs can help make headway against AIDS epidemic

Study suggests strong treatment programs can help make headway against AIDS epidemic

Botswana appears to have achieved very high rates of HIV diagnosis, treatment, and viral suppression--much better than most Western nations, including the United States--according to a new study from Harvard T.H. Chan School of Public Health and colleagues in Botswana. [More]
Antibodies given within one day of SHIV exposure can clear the virus

Antibodies given within one day of SHIV exposure can clear the virus

Scientists at the Oregon National Primate Research Center today revealed that infant rhesus macaques treated with antibodies within 24 hours of being exposed to SHIV, a chimeric simian virus that bears the HIV envelope protein, were completely cleared of the virus. [More]
Specialized gene editing system paves way to eventual cure for HIV patients

Specialized gene editing system paves way to eventual cure for HIV patients

A specialized gene editing system designed by scientists at the Lewis Katz School of Medicine at Temple University is paving the way to an eventual cure for patients infected with HIV, the virus that causes AIDS. [More]
Simple TB screening and isoniazid can be effective for HIV patients at risk for TB

Simple TB screening and isoniazid can be effective for HIV patients at risk for TB

The number one killer of HIV patients in resource-limited areas, including parts of Africa and India, is tuberculosis (TB), underscoring the need for optimal treatments and effective strategies to address this deadly co-infection. But TB is harder to detect in HIV-infected patients and diagnostic test results take time, so many healthcare providers prescribe multi-drug TB treatments as a precaution. [More]
Clinical study finds no added benefit of using four TB drugs to save people with advanced HIV/AIDS

Clinical study finds no added benefit of using four TB drugs to save people with advanced HIV/AIDS

In a report on the so-called REMEMBER (Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment) study -- a 10-nation, randomized clinical trial of adult outpatients -- investigators concluded that there was no added benefit of using four drugs for TB over just using one drug, isoniazid, to save lives in people with advanced HIV/AIDS. [More]
Study: Statin drugs can reduce time to clear tuberculosis infection in mice

Study: Statin drugs can reduce time to clear tuberculosis infection in mice

In a study using mice, the Johns Hopkins University School of Medicine infectious disease experts have added to evidence that statin drugs — known primarily for their cholesterol-lowering effects — can significantly reduce the time it takes to clear tuberculosis infection. [More]
Low bone mass higher in HIV-infected males than in females

Low bone mass higher in HIV-infected males than in females

Accumulating evidence suggests that rates of low bone mass are greater in HIV-infected males than in females. Researchers led by Grace Aldrovandi, MD, chief of the Division of Infectious Diseases at Children's Hospital Los Angeles, studied 11 biomarkers associated with inflammation, bone loss and/or bone formation in about 450 individuals - assessed by sex and HIV status - to try to determine causes of this differential bone loss. [More]
VIGH study seeks to eliminate mother-to-child transmission of HIV in Africa

VIGH study seeks to eliminate mother-to-child transmission of HIV in Africa

Mother-to-child transmission of the human immunodeficiency virus (HIV), which causes AIDS, is still a major problem in resource-limited, rural areas of the world where health care providers are scarce. [More]
Study: 2.3 million people living with HIV co-infected with HCV

Study: 2.3 million people living with HIV co-infected with HCV

An estimated 2.3 million people living with HIV are co-infected with hepatitis C virus (HCV) globally, a new study by the University of Bristol and the London School of Hygiene & Tropical Medicine has found. [More]
Lewin-Cameron Laboratory at Doherty Institute selects OpenSpecimen system to manage biospecimens inventory

Lewin-Cameron Laboratory at Doherty Institute selects OpenSpecimen system to manage biospecimens inventory

In the short time that AXT have been promoting OpenSpecimen, the bioinformatics platform for managing biospecimens inventory developed by Krishagni Solutions in conjunction with the National Cancer Institute, it has generated large amounts of interest in Australia. [More]
Antidepressant paroxetine suppresses inflammation in people with HIV-related cognitive impairment

Antidepressant paroxetine suppresses inflammation in people with HIV-related cognitive impairment

In a small, placebo-controlled clinical trial, Johns Hopkins physicians report that the antidepressant paroxetine modestly improves decision-making and reaction time, and suppresses inflammation in people with HIV-associated cognitive impairment. The researchers say they believe this is the first time that a SSRI (selective serotonin reuptake inhibitor) has been shown to improve key measures of cognition in people with HIV in a controlled study. [More]
Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk for acquiring HIV. [More]
Sangamo presents immunological data from SB-728-T HIV clinical study at CROI 2016

Sangamo presents immunological data from SB-728-T HIV clinical study at CROI 2016

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of immunological data from the Company's clinical trials of SB-728-T, a ZFP Therapeutic designed to provide functional control of HIV. [More]
New approach to prevent mother to child transmission of HIV

New approach to prevent mother to child transmission of HIV

The first findings from a study in the Kingdom of Swaziland on a new approach to reduce mother to child transmission of HIV were presented at the annual Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston. [More]
Single dose of zoledronic acid can inhibit bone loss in HIV-infected patients

Single dose of zoledronic acid can inhibit bone loss in HIV-infected patients

A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy (ART). [More]
Advertisement
Advertisement